Skip to main content
Erschienen in: Journal of Gastroenterology 11/2016

12.03.2016 | Original Article—Liver, Pancreas, and Biliary Tract

Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease

verfasst von: Teruki Miyake, Teru Kumagi, Masashi Hirooka, Shinya Furukawa, Osamu Yoshida, Mitsuhito Koizumi, Shin Yamamoto, Takao Watanabe, Yasunori Yamamoto, Yoshio Tokumoto, Eiji Takeshita, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa

Erschienen in: Journal of Gastroenterology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Fatty liver disease is associated with glucose intolerance and hepatic insulin resistance. However, there are distinct etiologies for alcoholic versus non-alcoholic fatty liver disease (NAFLD), and it is unknown whether alcohol consumption influences the onset of glucose intolerance in fatty liver disease patients. Therefore, we investigated the relationship between fatty liver disease and the onset of impaired fasting glucose (IFG) with respect to alcohol consumption.

Methods

The records of 6804 Japanese subjects were reviewed to identify those meeting the criteria for IFG. Male and female subjects were classified into five and four groups, respectively, based on average alcohol consumption (g/week). IFG onset was defined as fasting plasma glucose levels ≥110 mg/dl.

Results

In the non-drinker, >0–70 g/week, >70–140 g/week, >140–210 g/week (men only), and >210 g/week (men only) or >140 g/week (women only) groups, 7.3, 6.7, 6.4, 9, and 6.4 % of men and 2, 1.7, 3.1, and 3.2 % of women, respectively, developed IFG. Fatty liver was positively associated with the onset of IFG in men of the >0–70 g/week group (adjusted hazard ratio [aHR], 2.808; 95 % confidence interval [CI] 1.605–5.049, p < 0.001) and women of the >70–140 g/week group (aHR, 4.193; 95 % CI, 1.036–14.584, p = 0.045) after adjusting for previously reported IFG risk factors. No associations were observed in the other groups.

Conclusions

A small amount of alcohol consumption is a significant risk factor for the onset of IFG in NAFLD patients; onset risk differs according to the amount of alcohol consumption.
Literatur
1.
Zurück zum Zitat Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.CrossRefPubMed Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.CrossRefPubMed
2.
Zurück zum Zitat Norgaard ML, Andersen SS, Schramm TK, et al. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction–a nationwide study. Diabetologia. 2010;53:1612–9.CrossRefPubMed Norgaard ML, Andersen SS, Schramm TK, et al. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction–a nationwide study. Diabetologia. 2010;53:1612–9.CrossRefPubMed
3.
Zurück zum Zitat Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalisation, and healthcare utilization. Am J Manag Care. 2008;14:15–23.PubMedPubMedCentral Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalisation, and healthcare utilization. Am J Manag Care. 2008;14:15–23.PubMedPubMedCentral
4.
Zurück zum Zitat Chang HY, Weiner JP, Richards TM, et al. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18:721–6.PubMed Chang HY, Weiner JP, Richards TM, et al. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18:721–6.PubMed
5.
Zurück zum Zitat Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med. 2002;19:708–23.CrossRefPubMed Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med. 2002;19:708–23.CrossRefPubMed
6.
Zurück zum Zitat Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78:305–12.CrossRefPubMed Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78:305–12.CrossRefPubMed
7.
Zurück zum Zitat Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708–23.CrossRefPubMed Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708–23.CrossRefPubMed
8.
Zurück zum Zitat Moebus S, Stang A, Möhlenkamp S, et al. Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort-results of Heinz Nixdorf Recall Study. Diabetologia. 2009;52:81–9.CrossRefPubMed Moebus S, Stang A, Möhlenkamp S, et al. Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort-results of Heinz Nixdorf Recall Study. Diabetologia. 2009;52:81–9.CrossRefPubMed
9.
Zurück zum Zitat Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes–pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335–48.CrossRefPubMed Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes–pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335–48.CrossRefPubMed
10.
Zurück zum Zitat Kotronen A, Vehkavaara S, Seppälä-Lindroos A, et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007;293:E1709–15.CrossRefPubMed Kotronen A, Vehkavaara S, Seppälä-Lindroos A, et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007;293:E1709–15.CrossRefPubMed
11.
Zurück zum Zitat Kim CH, Park JY, Lee KU, et al. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008;25:476–81.CrossRefPubMed Kim CH, Park JY, Lee KU, et al. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008;25:476–81.CrossRefPubMed
12.
Zurück zum Zitat Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25:352–6.CrossRefPubMed Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25:352–6.CrossRefPubMed
13.
Zurück zum Zitat Sung KC, Jeong WS, Wild SH, et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35:717–22.CrossRefPubMedPubMedCentral Sung KC, Jeong WS, Wild SH, et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35:717–22.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889–95.CrossRefPubMed Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889–95.CrossRefPubMed
15.
Zurück zum Zitat Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.CrossRefPubMedPubMedCentral Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004;53:2623–32.CrossRefPubMed Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004;53:2623–32.CrossRefPubMed
17.
Zurück zum Zitat Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913–8.CrossRefPubMed Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913–8.CrossRefPubMed
18.
Zurück zum Zitat Ford ES, Schulze MB, Bergmann MM, et al. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008;31:1138–43.CrossRefPubMed Ford ES, Schulze MB, Bergmann MM, et al. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008;31:1138–43.CrossRefPubMed
19.
Zurück zum Zitat Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 2008;57:387–92.CrossRefPubMed Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 2008;57:387–92.CrossRefPubMed
20.
Zurück zum Zitat Balkau B, Lange C, Vol S, et al. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010;10:56.CrossRefPubMedPubMedCentral Balkau B, Lange C, Vol S, et al. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010;10:56.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954–61.CrossRefPubMed Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954–61.CrossRefPubMed
23.
Zurück zum Zitat Kuzuya T, Nakagawa S, Satoh J, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65–85.CrossRefPubMed Kuzuya T, Nakagawa S, Satoh J, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65–85.CrossRefPubMed
24.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.CrossRefPubMed
25.
Zurück zum Zitat American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2003;26:S21–4.CrossRef American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2003;26:S21–4.CrossRef
26.
Zurück zum Zitat Harita N, Hayashi T, Sato KK, et al. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care. 2009;32:424–6.CrossRefPubMedPubMedCentral Harita N, Hayashi T, Sato KK, et al. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care. 2009;32:424–6.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Jimba S, Nakagami T, Takahashi M, et al. Prevalence of nonalcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141–5.CrossRefPubMed Jimba S, Nakagami T, Takahashi M, et al. Prevalence of nonalcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141–5.CrossRefPubMed
28.
Zurück zum Zitat Sairenchi T, Iso H, Nishimura A, et al. Cigarette smoking and risk of type 2 diabetes mellitus among middle-aged and elderly Japanese men and women. Am J Epidemiol. 2004;160:158–62.CrossRefPubMed Sairenchi T, Iso H, Nishimura A, et al. Cigarette smoking and risk of type 2 diabetes mellitus among middle-aged and elderly Japanese men and women. Am J Epidemiol. 2004;160:158–62.CrossRefPubMed
29.
Zurück zum Zitat Waki K, Noda M, Sasaki S, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med. 2005;22:323–31.CrossRefPubMed Waki K, Noda M, Sasaki S, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med. 2005;22:323–31.CrossRefPubMed
30.
Zurück zum Zitat Miyake T, Kumagi T, Furukawa S, et al. Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study. PLoS One. 2014;9:e107882.CrossRefPubMedPubMedCentral Miyake T, Kumagi T, Furukawa S, et al. Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study. PLoS One. 2014;9:e107882.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes mellitus in middle-aged Japanese men. Diabetes Care. 2007;30:2940–4.CrossRefPubMed Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes mellitus in middle-aged Japanese men. Diabetes Care. 2007;30:2940–4.CrossRefPubMed
32.
Zurück zum Zitat Yamazaki H, Tsuboya T, Tsuji K, et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes mellitus. Diabetes Care. 2015;38:1673–9.CrossRefPubMed Yamazaki H, Tsuboya T, Tsuji K, et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes mellitus. Diabetes Care. 2015;38:1673–9.CrossRefPubMed
33.
Zurück zum Zitat Su CC, Wang K, Hsia TL, et al. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol. 2006;40:551–4.CrossRefPubMed Su CC, Wang K, Hsia TL, et al. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol. 2006;40:551–4.CrossRefPubMed
34.
Zurück zum Zitat Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated enzymes. Hepatology. 2006;44:865–73.CrossRefPubMed Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated enzymes. Hepatology. 2006;44:865–73.CrossRefPubMed
35.
Zurück zum Zitat Fromenty B, Vadrot N, Massart J, et al. Chronic ethanol consumption lessens the gain of body weight, liver triglycerides, and diabetes in obese ob/ob mice. J Pharmacol Exp Ther. 2009;331:23–34.CrossRefPubMed Fromenty B, Vadrot N, Massart J, et al. Chronic ethanol consumption lessens the gain of body weight, liver triglycerides, and diabetes in obese ob/ob mice. J Pharmacol Exp Ther. 2009;331:23–34.CrossRefPubMed
36.
Zurück zum Zitat Moriya A, Iwasaki Y, Ohguchi S, et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol. 2015;62:921–7.CrossRefPubMed Moriya A, Iwasaki Y, Ohguchi S, et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol. 2015;62:921–7.CrossRefPubMed
37.
Zurück zum Zitat Koppes LL, Dekker JM, Hendriks HF, et al. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care. 2005;28:719–25.CrossRefPubMed Koppes LL, Dekker JM, Hendriks HF, et al. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care. 2005;28:719–25.CrossRefPubMed
38.
Zurück zum Zitat Joosten MM, Beulens JW, Kersten S, et al. Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomized, cross-over trial. Diabetologia. 2008;51:1375–81.CrossRefPubMedPubMedCentral Joosten MM, Beulens JW, Kersten S, et al. Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomized, cross-over trial. Diabetologia. 2008;51:1375–81.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Sierksma A, Patel H, Ouchi N, et al. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care. 2004;27:184–9.CrossRefPubMed Sierksma A, Patel H, Ouchi N, et al. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care. 2004;27:184–9.CrossRefPubMed
40.
Zurück zum Zitat You M, Considine RV, Leone TC, et al. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. 2005;42:568–77.CrossRefPubMedPubMedCentral You M, Considine RV, Leone TC, et al. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. 2005;42:568–77.CrossRefPubMedPubMedCentral
41.
42.
Zurück zum Zitat Ekstedt M, Franzén LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44:366–74.CrossRefPubMed Ekstedt M, Franzén LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2009;44:366–74.CrossRefPubMed
43.
Zurück zum Zitat Wang Y, Seitz HK, Wang XD. Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats. Alcohol Clin Exp Res. 2010;34:567–73.CrossRefPubMed Wang Y, Seitz HK, Wang XD. Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats. Alcohol Clin Exp Res. 2010;34:567–73.CrossRefPubMed
44.
Zurück zum Zitat Nascimento AF, Ip BC, Luvizotto RA, et al. Aggravation of nonalcoholic steatohepatitis by moderate alcohol consumption is associated with decreased SIRT1 activity in rats. Hepatobiliary Surg Nutr. 2013;2:252–9.PubMedPubMedCentral Nascimento AF, Ip BC, Luvizotto RA, et al. Aggravation of nonalcoholic steatohepatitis by moderate alcohol consumption is associated with decreased SIRT1 activity in rats. Hepatobiliary Surg Nutr. 2013;2:252–9.PubMedPubMedCentral
45.
Zurück zum Zitat Gäbele E, Dostert K, Dorn C, et al. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcohol Clin Exp Res. 2011;35:1361–7.CrossRefPubMed Gäbele E, Dostert K, Dorn C, et al. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcohol Clin Exp Res. 2011;35:1361–7.CrossRefPubMed
Metadaten
Titel
Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease
verfasst von
Teruki Miyake
Teru Kumagi
Masashi Hirooka
Shinya Furukawa
Osamu Yoshida
Mitsuhito Koizumi
Shin Yamamoto
Takao Watanabe
Yasunori Yamamoto
Yoshio Tokumoto
Eiji Takeshita
Masanori Abe
Kohichiro Kitai
Bunzo Matsuura
Yoichi Hiasa
Publikationsdatum
12.03.2016
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 11/2016
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1194-0

Weitere Artikel der Ausgabe 11/2016

Journal of Gastroenterology 11/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.